Evolus, Inc. (EOLS) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. Evolus, Inc. is a global performance beauty company focused on the cash-pay aesthetic market. Its primary commercial products are Jeuveau (prabotulinumtoxinA-xvfs), a neurotoxin for glabellar lines, and the Evolysse collection of injectable hyaluronic acid (HA) gels. The company operates as a single reporting segment.
Key Financial Metrics (Six Months Ended June 30, 2026)
| Metric | Value (in thousands) |
|---|---|
| Total Net Revenues | $157,221 |
| Gross Profit | $106,077 |
| Gross Margin | 67.5% |
| Net Loss | $(18,726) |
| Loss Per Share (Basic & Diluted) | $(0.29) |
| Cash and Cash Equivalents (End of Period) | $45,170 |
| Long-Term Debt (Principal) | $160,000 |
| Accumulated Deficit | $(679,766) |
| Net Cash Used in Operating Activities | $(13,539) |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased by 14.0% ($19.3 million) compared to the six months ended June 30, 2025, driven by higher sales of both Jeuveau and Evolysse.
- Profitability Improvement: Net loss narrowed significantly to $18.7 million from $36.0 million in the prior year period. Loss from operations improved to $11.4 million from $25.4 million.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses decreased by 3.8% ($4.3 million) year-over-year, attributed to lower marketing costs following the completion of strategic cost optimization initiatives in late 2025.
- Interest Expense: Net interest expense decreased by 27.5% ($2.9 million), primarily due to the absence of $3.0 million in debt modification fees recognized in the prior year.
- Tariff Refunds: The company recognized a reduction in cost of goods sold of $1.1 million due to the recovery of tariffs previously paid under the International Emergency Economic Powers Act (IEEPA).
Guidance, Outlook, and Risks
- Liquidity: Management believes current capital resources (cash, operating cash flow, and debt facilities) are sufficient to fund operations for at least the next twelve months. The company maintains a $30 million Revolving Credit Facility and up to $250 million in New Pharmakon Term Loans.
- Product Pipeline:
- Evolysse: Launched four products in Europe in May 2026. Anticipates U.S. approval for Evolysse Sculpt in Q4 2026 and Evolysse Lips in 2027.
- Profhilo: Entered an exclusive license agreement with IBSA in July 2026 for U.S. rights to Profhilo, with commercialization anticipated in 2030.
- Tariff Risks: Significant uncertainty remains regarding U.S. trade policy. Evolysse (imported from EU) is subject to a 10% tariff. Jeuveau (manufactured in South Korea) faces a potential 15% tariff starting September 29, 2026. The company has accelerated inventory purchases to mitigate near-term exposure.
- Contingent Obligations: The company has significant contingent royalty obligations to Evolus Founders (fair value $29.0 million) and milestone payment obligations to Symatese and Medytox.
Investor Verification Checklist
- Tariff Impact: Verify the actual implementation and scope of the 15% tariff on Jeuveau imports from South Korea effective September 2026 and the company's ability to pass costs to consumers.
- Debt Covenants: Confirm continued compliance with the minimum excess availability covenant under the Revolving Credit Facility and other restrictive covenants in the Pharmakon Term Loans.
- Regulatory Approvals: Monitor the timeline for FDA approval of Evolysse Sculpt and Lips, as delays could impact revenue projections and trigger minimum purchase obligation reviews.
- Supplier Concentration: Assess risks related to sole-source manufacturing dependencies on Daewoong (Jeuveau) and Symatese (Evolysse), particularly regarding supply chain disruptions or quality issues.
- Cash Burn Rate: Track the trajectory of operating cash burn against the $45.2 million cash balance to ensure the 12-month liquidity runway remains valid given potential tariff-related inventory costs.